Moderna's flu vaccine has survived the regulatory gauntlet. Its financial survival is a harder test

THE FDA'S CLOCK on Moderna's mRNA flu vaccine expires today. On 5 August the agency's PDUFA deadline - a legally binding timetable for drug reviews - runs out, and Moderna will learn whether mFLUSIVA, the first seasonal influenza shot built on messenger RNA technology, is cleared for the market.

The substance of the decision was effectively settled on 18 June, when an FDA advisory panel voted 9-0 to recommend approval for adults aged 50 and over. The agency rarely goes against its panels. The remaining drama is bureaucratic, not scientific.

The real question is not whether Moderna's vaccine will be approved. It is whether the company can turn approval into a business that saves it.

The clinical data are not a sensation, but they are solid. A phase 3 trial published in the New England Journal of Medicine, involving more than 40,000 adults across 11 countries, found that mRNA-1010 reduced influenza illness by 27% compared with a standard-dose flu shot. That meets the criteria for non-inferiority and for superiority. Efficacy was broadly consistent across the three strains tested: 30% against H1N1, 22% against H3N2, and 29% against the B/Victoria lineage. Serious adverse events were uncommon and occurred at similar rates in both groups - 2.2% versus 1.9%. The downside is more reactogenicity: injection-site pain hit 66% of mRNA recipients versus 30% of standard-dose recipients. That is an inconvenience, not a show-stopper.

To be sure, the trial was run over a single flu season and captured fewer cases of influenza B than Moderna expected. The severity of the 2024-25 flu season meant the trial accrued cases faster than planned, leaving less time for the B strain to circulate. Panel members acknowledged this gap. But the data were deemed "very convincing," as Stanley Perlman, a paediatric disease expert at the University of Iowa, put it at the advisory meeting.

The regulatory path has been anything but smooth. In February the FDA sent Moderna a refusal-to-file letter - an unusual move, sent when an agency deems an application incomplete, especially after months of pre-filing dialogue. Moderna published the letter and accused the FDA of backtracking on agreed trial parameters. The refusal came under Vinay Prasad, then the FDA's top vaccine official, who claimed Moderna had not compared its vaccine against "the best-available standard of care." That phrase, as legal scholars noted, has no basis in FDA statute. A week later, the agency reversed course.

The flip-flop was not merely procedural. It reflected a broader political campaign against mRNA technology under Health and Human Services Secretary Robert F. Kennedy Jr, who has openly questioned the safety of mRNA vaccines and whose department cancelled nearly $500m in mRNA research funding last summer. Mr Prasad and former FDA commissioner Marty Makary, both of whom had imposed stricter standards on certain vaccines, have since departed. The interim leadership appears more traditional. That matters for Moderna now. It also matters for hundreds of smaller biotechs working on mRNA therapies for everything from Lyme disease to cancer, whose investors have grown spooked, according to Jeff Coller, a professor at Johns Hopkins University.

"When you see the FDA rejecting a product that comes from Moderna, why is it that my little company would be able to push through?" he asks.

The regulatory turbulence is a distraction from the structural problem Moderna faces, which is arithmetic. The company made $1.9bn in revenue across fiscal 2025, a precipitous decline from its pandemic-era peak in 2021 when COVID-19 demand was at its height. In the first quarter of 2026 revenue recovered modestly to $389m, driven almost entirely by international COVID-19 sales; roughly 80% came from outside the United States. The second quarter was weaker again, at $145m. Moderna lost $782m in the second quarter of 2026, and $2.8bn for all of 2025. The stock, which peaked at $484 in August 2021, trades at $56. Its market capitalisation is approximately $23bn.

A $23bn valuation for a company that burns nearly $3bn a year in net losses is not a bet on what Moderna does today. It is a bet on what it might do tomorrow. The flu vaccine is the nearest-term pillar of that bet.

The global influenza vaccine market is large and growing, depending on the analyst. It is dominated by Sanofi, Seqirus (part of CSL) and AstraZeneca, all of which use egg-based or cell-culture production. Moderna's advantage is speed: mRNA can be updated in weeks when a new strain emerges, whereas egg-based production can take months and sometimes introduces mutations that reduce the match between vaccine and circulating virus. But the flu market is low-margin, highly competitive and subject to seasonal demand swings. Even if Moderna wins a meaningful share, the revenue will not replace COVID-19 overnight.

That is the trade-off the market has already started to price in. Q2 revenue of $145m came in above the consensus estimate of $121m, suggesting some near-term momentum. mFLUSIVA, if approved, will be sold at select retailers for the 2026-27 flu season, which runs from autumn. The bulk of flu revenue will arrive in the fourth quarter of 2026 and beyond.

Moderna's pipeline beyond flu offers more options but more uncertainty. The company has an RSV vaccine (mRESVIA) approved in Europe. A norovirus vaccine is in phase 3, with data expected in 2026. Its cancer vaccine programme, intismeran autogene, has entered phase 3 for non-small cell lung cancer. Regulatory filings have been submitted in the EU, Canada and Australia for flu. Each represents a potential revenue stream. Each also requires investment that the company currently funds by running down its cash.

The broader lesson is about the lifecycle of pandemic-era biotechs. When COVID-19 receded, it exposed companies whose revenue bases were built on a single event. Moderna, like its rival BioNTech, has tried to diversify into infectious disease, oncology and rare disease. The platform is real: mRNA technology won a Nobel Prize for good reason. But platforms that can make anything are not the same as products that sell.

For investors, the relevant risk is not whether the FDA will approve mFLUSIVA. It almost certainly will. The risk is whether flu sales can grow fast enough to slow the burn and justify a $23bn market capitalisation for a company that does not yet have a recurring, profitable core business. The stock has rallied from a 52-week low of $22, partly on flu vaccine momentum. But the path from approval to profitability is long, competitive, and seasonal.

The flu vaccine is a vindication of Moderna's science and a repudiation of the political interference that nearly derailed it. It is not, by itself, a solution to the company's financial trajectory. Approval is a milestone. Revenue is the test.

That is always the harder one.